Empagliflozin combined with bortezomib in the treatment of heavy and light chain amyloidosis with secondary diabetes: A case report.

ABSTRACT:

Rationale

Primary heavy and light chain amyloidosis (AHL) is extremely rare globally. This study aimed to report the first clinical treatment of AHL secondary diabetes. We also analyzed fasting blood glucose levels across various treatments. Finally, a reference was provided for treatment and laboratory indicators in AHL with secondary diabetes.

Patient concerns

The patient was treated in Department of Hematology in Deyang People's Hospital. He underwent treatment with daratumumab (DARA) + cyclophosphamide, bortezomib, and dexamethasone (CyBorD), autologous stem cell transplantation and bortezomib for AHL, alongside empagliflozin for blood glucose management. Clinical data and laboratory results were collected during phases of treatment and follow-up.

Diagnoses

This p

SUBMITTER: Zhang N 

PROVIDER: S-EPMC12367034 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature